Non-Melanoma Skin Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
201 Pages
December 2023
Region: Global
Fairfield Market Research
ID: 5915986

Non-melanoma skin cancer is a condition that, when not treated properly, can quickly escalate and pose serious health risks. Governments and regulatory bodies worldwide are stepping up efforts to educate the public about non-melanoma skin cancer and its significant impact on both individual health and the nation's economy.

Developed countries, in particular, are actively addressing this issue. One notable example is Cancer Council Australia, which has launched the SunSmart program. This initiative aims to raise awareness about non-melanoma skin cancer, and its significance cannot be understated, as Australia currently experiences the highest prevalence of this condition in the Asia-Pacific (APAC) region.

Non-Melanoma Skin Cancer and Radiation Therapy

In cases where surgical removal is not feasible, radiation therapy is employed to treat non-melanoma skin cancer lesions, particularly in areas such as the nose tip, eyelids, and other extremities.

Superficial Radiation Therapy for Reduced Side Effects

Recent advancements in medical technology have led to the development of standalone radiation therapy machines, which have gained widespread acceptance in dermatology clinics for the treatment of non-melanoma skin cancer. These portable devices offer the advantage of causing fewer side effects compared to conventional radiation therapy methods.

Sensus Healthcare, a leading player in this field, has designed Superficial Radiation Therapy (SRT) devices specifically for the treatment of non-melanoma skin cancer. These devices are highly effective and offer a more economical solution when compared to traditional radiation therapy equipment. They have become a preferred choice for healthcare professionals due to their effectiveness and reduced side effects.

Government initiatives and advancements in medical technology are pivotal in the fight against non-melanoma skin cancer. Raising awareness and providing access to innovative treatments like SRT radiation therapy devices are crucial steps toward improving the outcomes for individuals affected by this condition.

Market Segmentation

Treatment Type:

Radiation Therapy
External Beam Radiation Therapy
Electronic Brachytherapy
Superficial Radiation Therapy
Chemotherapy
Photodynamic Therapy

Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Indication:

Basal Cell Carcinoma
Squamous Cell Carcinoma

End User:

Hospitals
Ambulatory Surgical Centers
Specialty Clinics

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Non-Melanoma Skin Cancer Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Non-Melanoma Skin Cancer Market Outlook, 2018 - 2031

3.1. Global Non-Melanoma Skin Cancer Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Radiation Therapy
3.1.1.1.1. External Beam Radiation Therapy
3.1.1.1.2. Electronic Brachytherapy
3.1.1.1.3. Superficial Radiation Therapy
3.1.1.2. Chemotherapy
3.1.1.3. Photodynamic Therapy
3.2. Global Non-Melanoma Skin Cancer Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Basal Cell Carcinoma
3.2.1.2. Squamous Cell Carcinoma
3.3. Global Non-Melanoma Skin Cancer Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Ambulatory Surgical Centers
3.3.1.3. Specialty Clinics
3.4. Global Non-Melanoma Skin Cancer Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Non-Melanoma Skin Cancer Market Outlook, 2018 - 2031

4.1. North America Non-Melanoma Skin Cancer Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Radiation Therapy
4.1.1.1.1. External Beam Radiation Therapy
4.1.1.1.2. Electronic Brachytherapy
4.1.1.1.3. Superficial Radiation Therapy
4.1.1.2. Chemotherapy
4.1.1.3. Photodynamic Therapy
4.2. North America Non-Melanoma Skin Cancer Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Basal Cell Carcinoma
4.2.1.2. Squamous Cell Carcinoma
4.3. North America Non-Melanoma Skin Cancer Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospitals
4.3.1.2. Ambulatory Surgical Centers
4.3.1.3. Specialty Clinics
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Non-Melanoma Skin Cancer Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Non-Melanoma Skin Cancer Market Outlook, 2018 - 2031

5.1. Europe Non-Melanoma Skin Cancer Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Radiation Therapy
5.1.1.1.1. External Beam Radiation Therapy
5.1.1.1.2. Electronic Brachytherapy
5.1.1.1.3. Superficial Radiation Therapy
5.1.1.2. Chemotherapy
5.1.1.3. Photodynamic Therapy
5.2. Europe Non-Melanoma Skin Cancer Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Basal Cell Carcinoma
5.2.1.2. Squamous Cell Carcinoma
5.3. Europe Non-Melanoma Skin Cancer Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospitals
5.3.1.2. Ambulatory Surgical Centers
5.3.1.3. Specialty Clinics
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Non-Melanoma Skin Cancer Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Non-Melanoma Skin Cancer Market Outlook, 2018 - 2031

6.1. Asia Pacific Non-Melanoma Skin Cancer Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Radiation Therapy
6.1.1.1.1. External Beam Radiation Therapy
6.1.1.1.2. Electronic Brachytherapy
6.1.1.1.3. Superficial Radiation Therapy
6.1.1.2. Chemotherapy
6.1.1.3. Photodynamic Therapy
6.2. Asia Pacific Non-Melanoma Skin Cancer Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Basal Cell Carcinoma
6.2.1.2. Squamous Cell Carcinoma
6.3. Asia Pacific Non-Melanoma Skin Cancer Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospitals
6.3.1.2. Ambulatory Surgical Centers
6.3.1.3. Specialty Clinics
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Non-Melanoma Skin Cancer Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Non-Melanoma Skin Cancer Market Outlook, 2018 - 2031

7.1. Latin America Non-Melanoma Skin Cancer Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Radiation Therapy
7.1.1.1.1. External Beam Radiation Therapy
7.1.1.1.2. Electronic Brachytherapy
7.1.1.1.3. Superficial Radiation Therapy
7.1.1.2. Chemotherapy
7.1.1.3. Photodynamic Therapy
7.2. Latin America Non-Melanoma Skin Cancer Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
7.2.1.1. Basal Cell Carcinoma
7.2.1.2. Squamous Cell Carcinoma
7.3. Latin America Non-Melanoma Skin Cancer Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospitals
7.3.1.2. Ambulatory Surgical Centers
7.3.1.3. Specialty Clinics
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Non-Melanoma Skin Cancer Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Non-Melanoma Skin Cancer Market Outlook, 2018 - 2031

8.1. Middle East & Africa Non-Melanoma Skin Cancer Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Radiation Therapy
8.1.1.1.1. External Beam Radiation Therapy
8.1.1.1.2. Electronic Brachytherapy
8.1.1.1.3. Superficial Radiation Therapy
8.1.1.2. Chemotherapy
8.1.1.3. Photodynamic Therapy
8.2. Middle East & Africa Non-Melanoma Skin Cancer Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Basal Cell Carcinoma
8.2.1.2. Squamous Cell Carcinoma
8.3. Middle East & Africa Non-Melanoma Skin Cancer Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospitals
8.3.1.2. Ambulatory Surgical Centers
8.3.1.3. Specialty Clinics
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Non-Melanoma Skin Cancer Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Non-Melanoma Skin Cancer Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Non-Melanoma Skin Cancer Market by Indication, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Non-Melanoma Skin Cancer Market by End User, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By End User vs by Indication Heat map
9.2. Manufacturer vs by Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Almirall S.A.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Boehringer Ingelheim GmbH
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Bristol-Myers Squibb Company
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Eli Lilly and Company
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Elekta AB
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. F. Hoffmann-La Roche Ltd.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Merck & Co., Inc.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Novartis AG
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Mylan NV
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Sun Pharmaceutical Industries Ltd.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

Almirall S.A.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Elekta AB
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Mylan NV
Sun Pharmaceutical Industries Ltd.
Varian Medical Systems, Inc.
Sensus Healthcare
iCAD, Inc.
Accuray, Inc.
Ion Beam Applications SA.

Methodology

LOADING...

Non-Melanoma Skin Cancer and Radiation Therapy

Superficial Radiation Therapy for Reduced Side Effects

Market Segmentation

Treatment Type:

Region:

Indication:

End User:

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032

Non-Melanoma Skin Cancer - Global Strategic Business Report

Non-melanoma Skin Cancer Market 2024-2028

Metastatic Melanoma Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), By End-use, By Regional Outlook and Forecast, 2024 - 2031